CellBion Co., Ltd. (KOSDAQ:308430)
South Korea · Delayed Price · Currency is KRW 15,000
+260 (1.76%)
At close: Aug 14, 2026
CellBion Revenue
CellBion had revenue of 472.05M KRW in the quarter ending June 30, 2026, with 16.71% growth. This brings the company's revenue in the last twelve months to 2.15B, down -18.37% year-over-year. In the year 2025, CellBion had annual revenue of 1.95B, down -15.05%.
Revenue (ttm)
2.15B
Revenue Growth
-18.37%
P/S Ratio
90.22
Revenue / Employee
n/a
Employees
55
Market Cap
193.58B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.95B | -344.73M | -15.05% |
| Dec 31, 2024 | 2.29B | 818.55M | 55.64% |
| Dec 31, 2023 | 1.47B | -291.63M | -16.54% |
| Dec 31, 2022 | 1.76B | 846.00M | 92.27% |
| Dec 31, 2021 | 916.88M | -443.71M | -32.61% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| NOVAREX | 404.26B |
| Ahn-Gook Pharmaceutical | 330.05B |
| Cosmax Nbt | 308.56B |
| Kyung Dong Pharmaceutical | 198.27B |
| GC WellBeing | 179.05B |
| DAE HWA Pharmaceutical | 148.75B |
| HYUNDAI BIOLAND | 135.04B |
| High Tech Pharm | 69.05B |